COVID-19 Pediatric Follow-Up: Respiratory Long COVID-Associated Comorbidities and Lung Ultrasound Alterations in a Cohort of Italian Children

Children, Journal Year: 2024, Volume and Issue: 11(2), P. 166 - 166

Published: Jan. 27, 2024

In children, the factors that influence COVID-19 disease and its medium- long-term effects are little known. Our investigation sought to evaluate presence of comorbidity associated with respiratory long COVID manifestations in children study ultrasound abnormalities following SARS-CoV-2 infection. Children, who arrived at ‘Respiratory Diseases Pediatric Interest Unit’ Department Woman, Child, General Specialized Surgery University Campania ‘Luigi Vanvitelli’, were selected during timeframe from September 2021 October 2022. The diagnosed a infection occurred least one month before visit. All patients followed follow-up protocol, developed by Italian Society Respiratory (SIMRI), which included: collection data regarding illness history known allergic diseases; physical examination; BMI assessment; baseline spirometry after bronchodilation test; six-minute walking lung (LUS). cohort 104 participants symptoms (64.7% male, average age 8.92 years), 46.1% had fever other symptoms, 1% required hospitalization. analysis showed 58.4% was overweight. LUS positive 27.0% cases. A significant association observed score (p-value < 0.05). No associations found asthma or atopy.

Language: Английский

---

Long-term neuropsychiatric and neuropsychological impact of the pandemic in Italian COVID-19 family clusters, including children and parents

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(4), P. e0321366 - e0321366

Published: April 24, 2025

Aim This study investigated the long-term neuropsychiatric and neuropsychological impact of COVID-19 on children their parents in households with exposure. Methods A prospective cohort was conducted 46 families attending Follow-up Clinic at Department for Women’s Children’s Health, Padua (Italy) from December 2021 to November 2022. Self-perceived stress-related, emotional-behavioral, post-traumatic stress (PTSD-related) symptoms were assessed both parents. Children underlying conditions excluded study. Results total 81 (median age = 38 years [IQR: 43–48], females 44 [54.3%]), 77 8 5–11], 33 [42.9%]) participated Overall,125 (79%) (21%) participants classified as cases non-COVID-19 cases, respectively. The time interval between family outbreak psychological assessment ≤4 months (median=3 [IQR=0]) 89 (56.3%) >4 69 (43.8%) (median=11.5 [IQR=5–12]) participants. 136 (86.1%) reported stress-related symptoms, emotional being most common. positive correlation observed self-perceived within same (r=0.53, p=0.0005). Among aged 6–18 years, 16 (37.2%) had clinical scores internalizing Child Behavior Checklist (CBCL), while none 1.5–5 showed score symptoms. Similarly, difficulty Strengths Difficulties Questionnaire (SDQ 4–17) PTSD-related through Trauma Symptom Young (TSCYC) questionnaire non-clinical cut-offs 45 (84.9%) 43 (75.4%) 3–12 (TSCC) resulted cut-off 36 (92.3%) 8–18 years. While a higher prevalence found compared (p=.01), no differences emotional-behavioral two groups. Conclusions documented pandemic Italian family’s levels. Further research is needed confirm our findings explore effects families.

Language: Английский

---

Parents’ reports of colombian children’s neurobehavioral symptoms before, during, and after COVID-19 infection

Neurorehabilitation, Journal Year: 2025, Volume and Issue: 56(3), P. 315 - 324

Published: Feb. 25, 2025

Background COVID-19 disproportionately affected individuals from marginalized and underserved communities, little research has investigated how might have impacted neurobehavioral symptoms in children Latin America. What suggests that had a negative effect on this was worse for who were younger, lower education, or other chronic conditions. Objective The purpose of the current study to examine change (before, during, after) sample Colombian tested positive identify key predictors post-COVID impairments. Methods Neurobehavioral Symptom Inventory administered caregivers (92.90% female) 85 (51.80% by researchers Colombia. Data collected after child recovered with retrospective questions about child's function before during COVID-19, as well at time data collection. Results At domain level, reported large increases children's somatic symptoms, medium increase affective small cognitive vs. COVID-19. Caregivers also noted vs symptom only category see an improvement following infection (during after). Three separate linear regressions indicated greater severity significantly predicted (after COVID-19) severity, presence pre-existing respiratory disease severity. Conclusion This highlights importance evaluating treating post-COVID-19 among Colombia identifies need under-researched population. Future may whether early intervention rehabilitation strategies help improve group.

Language: Английский

---

Treatment of Severe Asthma: Case Report of Fast Action of Mepolizumab in a Patient with Recent SARS-CoV-2 Infection

Life, Journal Year: 2024, Volume and Issue: 14(9), P. 1063 - 1063

Published: Aug. 25, 2024

Asthma is one of the most common chronic inflammatory diseases childhood with a heterogeneous impact on health and quality life. Mepolizumab an antagonist interleukin-5, indicated as adjunct therapy for severe refractory eosinophilic asthma in adolescents children aged >6 years old. We present case 9 year-old boy who experienced several asthmatic exacerbations following SARS-CoV-2 infection, necessitating short-acting bronchodilators, oral corticosteroids, hospitalization. follow patient using validated questionnaires evaluation control: Children Control Test, Questionnaire, respiratory function tests, exhaled nitric oxide fraction. After 12 weeks from start mepolizumab, we found significant improvements lung function, reduction degree bronchial inflammation, No have been reported since initiation treatment mepolizumab. Respiratory infections, such those related to SARS-CoV-2, represent risk factor patients moderate forms asthma. In our experience, new episodes exacerbation, mepolizumab has allowed us improve control enhance life first doses. Although showed promise this child during results single cannot be generalized. Further studies are needed confirm its safety effectiveness.

Language: Английский

---

Advances in pediatrics in 2023: choices in allergy, analgesia, cardiology, endocrinology, gastroenterology, genetics, global health, hematology, infectious diseases, neonatology, neurology, pulmonology

˜The œItalian Journal of Pediatrics/Italian journal of pediatrics, Journal Year: 2024, Volume and Issue: 50(1)

Published: Nov. 14, 2024

In the last year, there have been many remarkable articles published in Italian Journal of Pediatrics. This review highlights papers that can be potentially helpful healthcare practice among most cited or accessed on journal website. We chosen key allergy, analgesics, cardiology, endocrinology, gastroenterology, genetics, global health, infectious diseases, neonatology, neurology and pulmonology. Advances understanding risk factors, mechanisms, diagnosis, treatment options prevention pediatric diseases discussed context subsequent steps. think progresses achieved 2023 will a significant impact management childhood.

Language: Английский

---

Introductory Chapter: Mental Health in Developmental Age

IntechOpen eBooks, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 16, 2024

NULL

Language: Английский

---

Promoting healthy sleep behaviors: a response to ‘Sleep behaviors predicted sleep disturbances among Chinese health science students: a cross-sectional study

Sleep And Breathing, Journal Year: 2023, Volume and Issue: 28(1), P. 379 - 380

Published: Aug. 9, 2023

Language: Английский

---